• Fulfilling

    Potential

    With the Science of Enzymes

  • Fulfilling

    Potential

    In the Treatment of 

    Gastrointestinal and Rare Diseases

  • Helping

    Patients

    Fulfill Their Potential

News & Media

Alcresta Therapeutics Announces Positive Results, RELiZORB® Increased Fat Absorption in Both Adult and Pediatric Patients with Cystic Fibrosis Receiving Enteral Nutrition

Jul 31, 2017

RELiZORB significantly increased plasma levels of omega-3 fatty acids and patients reported a decrease in the frequency of gastrointestinal symptoms in a Pivotal Clinical Trial

Alcresta Therapeutics Receives 510(K) Clearance For Use of RELiZORB® in Children

Jul 20, 2017

RELiZORB, The Only Digestive Enzyme Cartridge for Patients Requiring Supplemental Enteral Nutrition, Now Cleared to Help Children Suffering
From Fat Malabsorption

Alcresta Therapeutics’ RELiZORB™ Increases Fat Absorption in Adult and Pediatric Patients with Cystic Fibrosis Receiving Enteral Nutrition

Oct 28, 2016

RELiZORB significantly increased plasma levels of DHA and EPA fatty acids and patients report a decrease in the frequency and severity of gastrointestinal symptoms